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Intracerebral hemorrhage (ICH) accounts for about 10% 
of strokes and is associated with higher morbidity and 
mortality rates than other stroke subtypes. Despite its 
devastating effects and social burden, no proven treat-
ment has been consistently demonstrated to be effective 
in ameliorating ICH consequences [1]. 
Elevation in blood pressure (BP) is common in acute 
ICH and is associated with greater hematoma expansion 
and poor clinical outcomes [2]. That is why BP is 
considered a major target in the acute period of ICH [1]. 
However, although safe, the relationship between 
intensive BP reduction and improvement of outcomes 
has not been consistently demonstrated in large rando-
mized controlled trials [3-5]. 
The Intensive Blood Pressure Reduction in Acute 
Cerebral Hemorrhage Trial (INTERACT) showed a 
trend towards lower hematoma expansion at 24 hours in 
patients under an intensive BP management regimen 
(target systolic BP of <140 mm Hg) [3]. Despite the 
promising pilot results of INTERACT, INTERACT2 
failed to show a significant reduction in the rate of death 
or major disability with intensive BP lowering at 90 
days [4]. However, intensive BP lowering showed 
improvement on functional outcomes in an ordinal 
analysis of modified Rankin scale scores. Thus, 
INTERACT2 resulted in revisions of guidelines for the 
management of acute ICH, supporting systolic BP 
lowering to <140 mm Hg [1]. The more recent 
Antihypertensive Treatment of Acute Cerebral 
Hemorrhage II (ATACH-II) trial has not, however, 
corroborated INTERACT2 results [5]. 
Although both INTERACT and ATACH-II trials 
showed a trend to lower frequency of significant hema-
toma expansion in patients under intensive BP 
management [4-5],  several limitations in both trials and 
in INTERACT2 may have resulted in failing to 
demonstrate a clear overall effect on hematoma expan-
sion. First, small hematomas observed in these trials are 
not prone to present hematoma expansion and could 
have influenced that significant hematoma expansion 
rate in even the conservatively treated patients (15% in 
INTERACT, around 25% in INTERACT2 and 
ATACH-II) was lower than the one third seen in obser-
vational studies [2-5]. Second, hematoma expansion 
analyses were restricted to those patients with repeat 
computed tomography at 24 hours (only a third in 
INTERACT2), which may have biased selection  towards 








those patients with better clinical status at baseline [4]. 
Third, because many patients in non-intensive groups 
received therapy to lower BP in these trials, the results 
almost certainly underestimated the effects of intensive 
therapy on hematoma expansion. And fourth, a long 
time to achieve BP control. Antihypertensive treatment 
was started at a median of 4 hours from symptoms onset 
in INTERACT-2, and only a third of the intensive 
treatment group achieved the target systolic BP within 
the first hour of treatment [4]. Similarly, although 
ATACH-II reported BP control in nearly 90% of 
patients, it was achieved 2.5 hours after antihyper-
tensive treatment initiation [5]. Because hematoma 
expansion occurs in the first few hours after ICH onset, 
it is possible that this delay to achieve BP target could 
have mitigated any effect on outcomes. 
A meta-analysis of five randomized controlled trials 
revealed greater reduction of hematoma expansion with 
intensive BP management, supporting the hypothesis 
that intensive BP reduction attenuates hematoma 
expansion [6]. Additional data from a secondary 
analysis of INTERACT2 suggest that patents with the 
least hematoma expansion are those who achieve target 
systolic BP of <140 mm Hg within the first hour [7]. 
Thus, a key issue of therapeutic benefit of intensive BP 
reduction on hematoma expansion is likely to be time. 
A recent study showing that high prehospital systolic 
BP is related to larger ICH volume on admission 
reinforces this hypothesis [8]. These findings suggest 
that early and rapid BP lowering can be crucial to 
attenuate ICH expansion. Furthermore, studies have 
shown that other BP variables such BP variability are 
related to hematoma expansion and subsequent poor 
outcome, suggesting that not only is important to keep 
BP low but also to maintain it stable during the acute 
phase of ICH [2]. 
To achieve early and rapid BP lowering, it would be 
essential to design interventions to improve time 
metrics in patients with acute ICH, including early ICH 
diagnosis and BP lowering treatment initiation, as well 
as rapid BP target achievement using intravenous 
antihypertensive agents as soon as possible. Recent 
approaches include BP-lowering initiation by emergen-
cy medical services in two different scenarios: con-
ventional ambulances and mobile stroke units. In 
conventional ambulances, it is possible to start BP 
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transdermal agents by paramedics with an initial target 
systolic BP of <180 mm Hg in all patients with 
presumed stroke in a thrombolysis window, and con-
tinue BP lowering to <140 mm Hg after in-hospital ICH 
diagnosis. Conversely, diagnosis of ICH in mobile 
stroke units would allow not only to target systolic BP 
of <140 mm Hg in the prehospital setting, but also early 
administration of intravenous antihypertensive agents to 
allow a rapid BP lowering [8]. 
In our opinion, additional trials where patients with 
acute ICH were randomized to early, rapid, intensive, 
and maintained BP lowering are warranted. Such data 
could confirm the hypothesis that BP lowering attenu-
ates hematoma expansion and improves clinical out-
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